首页> 外文期刊>Photodiagnosis and photodynamics therapy >An Update On The Regulatory Status Of Pdt Photosensitizers In China
【24h】

An Update On The Regulatory Status Of Pdt Photosensitizers In China

机译:中国Pdt光敏剂监管状况的最新动态

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Numerous photosensitizers have been developed and evaluated in China. HiPorfin, a hematoporphyrin derivative (HpD) received the first regulatory approval in the early 2000s. Aila, a topical formulation containing predrug 5-aminolevulinic acid, received the regulatory approval in 2007. Recently, new drug applications have been filed for several hematoporphyrin derivatives and a zinc phthalocyanine (ZnPc) derivative. This short report will summarize the current regulatory status of Chinese photosensitizers developed for photodynamic therapy (PDT).
机译:在中国已经开发和评估了许多光敏剂。血卟啉衍生物(HpD)HiPorfin在2000年代初获得了首个监管批准。含有前药5-氨基乙酰丙酸的局部用药Aila于2007年获得监管批准。最近,一些血卟啉衍生物和酞菁锌(ZnPc)衍生物已被申请新药申请。这份简短的报告将总结为光动力疗法(PDT)开发的中国光敏剂的监管现状。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号